Literature DB >> 3369313

Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

B A Bengtsson1, S Edén, I Ernest, A Odén, B Sjögren.   

Abstract

In 1985, a follow-up investigation was performed of all patients with acromegaly (n = 166, 89 women and 77 men) seen over a 30-year period (1955-1984) at our Endocrine Unit, referral centre for the western region of Sweden (population 1.5 million). At the end of 1984, the prevalence of the disease was 6.9 per 10(5) inhabitants, the average incidence per year was 3.3 per million people. Mean age at diagnosis was 46.3 years and at death (n = 62) 64.1 years. About one-third of the patients (50/153), in whom it had been possible to estimate the total duration of the disease, had survived for more than 25 years. Mortality was, however, increased compared to the normal population. The observed number of deaths from vascular and malignant disorders was 32 and 15, respectively, compared to the expected numbers 9.0 (p less than 0.001) and 5.6 (p less than 0.01).

Entities:  

Mesh:

Year:  1988        PMID: 3369313     DOI: 10.1111/j.0954-6820.1988.tb15881.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  92 in total

Review 1.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

Review 2.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

3.  Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.

Authors:  J R Lindsay; E M McConnell; S J Hunter; D R McCance; B Sheridan; A B Atkinson
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 4.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

5.  Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease.

Authors:  A Uçar; Melike Tuğrul; Bülent Oğuz Erol; Ensar Yekeler; Banu Aydın; Seher Yıldız; Kemal Nişli; Firdevs Baş; Şükran Poyrazoğlu; Feyza Darendeliler; Nurçin Saka; Aylin Yetim Şahin; Yasin Yılmaz; Rüveyde Bundak
Journal:  Pediatr Cardiol       Date:  2018-02-01       Impact factor: 1.655

6.  Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.

Authors:  K S G Cunha; E P Barboza; E C Da Fonseca
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

7.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

9.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 10.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.